[{"orgOrder":0,"company":"Difgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DifGen Pharmaceuticals Completes Successful USFDA Audit of Its US Manufacturing Site Aveva Drug Delivery Systems; Also Launches its First Oral Thin Film Product, a Generic to Suboxone (Buprenorphine\/ Naloxone) in the US Laying a Solid Platform of Manufact","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"},{"orgOrder":0,"company":"Difgen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"DifGen Pharmaceuticals Successfully Launches A Second Product - Buprenorphine Transdermal System From Its US Manufacturing Site Aveva Drug Delivery Systems; Expanding Its Portfolio Of Manufacturing & Marketing US Made Transdermal Patches And Sublingual Fi","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Small molecule","productStatus":"Approved","date":"November 2023","url1":"","url2":"","graph1":"Psychiatry\/Psychology","graph2":"Approved"}]
Find Clinical Drug Pipeline Developments & Deals by Difgen
Buprenorphine Transdermal System is a partial opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.
Buprenorphine sublingual tablets, is a partial opioid agonist in combination with naloxone, an opioid antagonist, is indicated for the maintenance treatment of opioid dependence.